Corresponding Author: Jonathan M. Coutinho, MD, PhD, Department of Neurology, Amsterdam University Medical Center, Location AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands (firstname.lastname@example.org).
Accepted for Publication: May 31, 2021.
Published Online: July 2, 2021. doi:10.1001/jama.2021.9889
Author Contributions: Drs Sánchez van Kammen and Coutinho had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Sánchez van Kammen and Heldner shared first authorship. Drs Arnold and Coutinho shared last authorship.
Concept and design: Sánchez van Kammen, Heldner, Kremer Hovinga, Middeldorp, Levi, Ferro, Tatlisumak, Arnold, Coutinho.
Acquisition, analysis, or interpretation of data: Sánchez van Kammen, Heldner, Brodard, Scutelnic, Silvis, Schroeder, Kremer Hovinga, Levi, Hiltunen, Lindgren, Mansour, Arauz, Barboza, Zuurbier, Aguiar de Sousa, Fischer, Field, Jood, Tatlisumak, Putaala, Arnold, Coutinho.
Drafting of the manuscript: Sánchez van Kammen, Heldner, Brodard, Scutelnic, Kremer Hovinga, Arnold, Coutinho.
Critical revision of the manuscript for important intellectual content: Heldner, Brodard, Scutelnic, Silvis, Schroeder, Kremer Hovinga, Middeldorp, Levi, Hiltunen, Lindgren, Mansour, Arauz, Barboza, Zuurbier, Aguiar de Sousa, Ferro, Fischer, Field, Jood, Tatlisumak, Putaala, Arnold.
Statistical analysis: Sánchez van Kammen, Silvis.
Obtained funding: Kremer Hovinga, Coutinho.
Administrative, technical, or material support: Sánchez van Kammen, Heldner, Brodard, Scutelnic, Silvis, Schroeder, Kremer Hovinga, Levi, Barboza, Zuurbier, Tatlisumak, Putaala, Arnold.
Supervision: Kremer Hovinga, Middeldorp, Levi, Zuurbier, Aguiar de Sousa, Ferro, Tatlisumak, Putaala, Arnold, Coutinho.
Conflict of Interest Disclosures: Dr Heldner reported receiving grants from the Swiss Heart Foundation and Bangerter Foundation and travel support from Bayer and serving on the data safety and monitoring board (DSMB) or advisory board of Amgen. Dr Middeldorp reported receiving grants paid to her institution from Bayer, Pzifer, Boehringer Ingelheim, and Daiichi Sankyo and personal fees paid to her institution from Bayer, BMS/Pfizer, Boehringer Ingelheim, AbbVie, Portola/Alexion, and Daiichi Sankyo. Dr Lindgren reported receiving grants from the Swedish Neurological Society, the Elsa and Gustav Lindh Foundation, the P-O Ahl Foundation, and the Rune and Ulla Amlöv Foundation. Dr Barboza reported receiving payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Abbott, Pfizer, Roche, and Bayer. Dr Aguiar de Sousa reported receiving travel support from Boehringer Ingelheim, serving on the DSMB for the SECRET trial, and being a member of the European Stroke Organisation executive committee. Dr Ferro reported receiving personal fees and serving on the DSMB or advisory board for Boehringer Ingelheim and receiving consulting fees from Bayer. Dr Fischer reported receiving grants from Medtronic and the Swiss National Science Foundation and serving on the speakers bureau for Boehringer Ingelheim. Dr Field reported receiving grants from Bayer Canada and in-kind study medication for the SECRET trial and being an expert witness for the Canadian Medical Protective Association. Dr Tatlisumak reported receiving grants from the Sahlgrenska University Hospital, the University of Gothenburg, and the Sigrid Juselius Foundation during the conduct of the study; serving on the advisory boards and steering committees for Bayer and Bristol Myers Squibb and on the advisory boards of Boehringer Ingelheim and Portola. Dr Putaala reported receiving grants paid to his institution from the Academy of Finland, Hospital District of Helsinki and Uusimaa, and Finnish Foundation for Cardiovascular Research; receiving consulting fees from Boehringer Ingelheim, Bayer, and Herantis Pharma; receiving payment for honoraria, lectures, presentations, speakers bureaus, manuscript writing, or educational events from Boehringer Ingelheim, Bayer, and Abbott; serving as president of the Finnish Hypertension Society; and owning stock in Vital Signum. Dr Arnold reported receiving grants from the Swiss Heart Foundation and the Swiss National Science Foundation; honoraria for lectures from AstraZeneca, Bayer, Covidien, and Medtronic, and receiving honoraria for serving on the scientific advisory boards of Amgen, Bayer, Bristol Myers Squibb, Daichi Sankyo, Medtronic, Novartis, and Sanofi. Dr Coutinho reported receiving grants paid to his institution from Boehringer Ingelheim and Bayer, and payments to his institution for serving on a DSMB for Bayer. No other disclosures were reported.
Funding/Support: This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Plasma samples were used from a previous study, which was supported by grants from the Swiss Heart foundation (112/09) and Dutch Thrombosis Society (2012-2).
Role of the Funder/Sponsor: No organizations or companies had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
A , Thiele
T , Warkentin
TE , Weisser
K , Kyrle
PA , Eichinger
S . Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med
. Published online April 9, 2021. doi:10.1056/NEJMoa2104840
NH , Sørvoll
IH , Michelsen
et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med
. Published online April 9, 2021. doi:10.1056/NEJMoa2104882
JR , Su
JR , Broder
et al. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients—United States, April 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(17):651-656. doi:10.15585/mmwr.mm7017e4
G , Warkentin
TE , Farooqi
MAM , Jevtic
SD , Zeller
MP , Perera
KS . Spontaneous heparin-induced thrombocytopenia syndrome presenting as cerebral venous sinus thrombosis. Neurol Clin Pract
. Published online January 14, 2020.Google Scholar
P , Ruiz-Giménez
N , Nieto
et al; RIETE investigators. Platelet count and outcome in patients with acute venous thromboembolism. Thromb Haemost
. 2013;110(5):1025-1034. doi:10.1160/TH13-04-0352
SM , Reinstra
E , Hiltunen
et al; International CVT Consortium. Anaemia at admission is associated with poor clinical outcome in cerebral venous thrombosis. Eur J Neurol
. 2020;27(4):716-722. doi:10.1111/ene.14148
G , Barinagarrementeria
F , Brown
et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke
. 2011;42(4):1158-1192. doi:10.1161/STR.0b013e31820a8364
JM , Bousser
MG , Canhão
et al; European Stroke Organization. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology. Eur J Neurol
. 2017;24(10):1203-1213. doi:10.1111/ene.13381
DR , Albert
M , Heels-Ansdell
et al; PROTECT collaborators, the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest
. 2013;144(4):1207-1215. doi:10.1378/chest.13-0121
I , Sachs
UJ , Arnold
et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost
. 2021;19(6):1585-1588. doi:10.1111/jth.15341